Clinical Trials Browser

OTHER × pazopanib × Sarcoma × Clear all

NCT07444619 2026-03-03

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

Phase 1 Not yet recruiting

Sarcoma

NCT04199026 2026-02-19

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Phase NA Recruiting

Sarcoma

NCT05180695 2026-02-10

AMPHISARC

Phase 1/2 Active not recruiting

Sarcoma

NCT06239272 2026-01-26

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Phase 1/2 Recruiting

Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT05679921 2025-07-16

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Phase 2 Recruiting

Sarcoma

NCT01543763 2025-03-21

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Phase 1 Completed

Neoplasm Metastasis, Sarcoma, Disease Progression

NCT06816771 2025-02-10

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

Phase 2 Recruiting

Recurrence, Rhabdomyosarcoma

NCT02203760 2024-11-15

PazoDoble

Phase 2 Active not recruiting

Carcinosarcoma, Leiomyosarcoma, Recurrence

NCT02207309 2024-08-09

Pazopanib Maintenance Phase II

Phase 2 Terminated

1 enrolled 4 charts

Sarcoma

NCT04741438 2023-08-30

RAR-Immune

Phase 3 Unknown

Sarcoma

NCT02066285 2023-03-27

Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma

Phase 2 Completed

Chondrosarcoma, Extraskeletal Myxoid, Neoplasm Metastasis, Solitary Fibrous Tumors

NCT01462630 2022-08-19

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Phase 2 Completed

29 enrolled 10 charts

Hemangiosarcoma, Sarcoma

NCT02357810 2022-06-07

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Phase 2 Completed

178 enrolled 16 charts

Liposarcoma, Sarcoma, Osteosarcoma

NCT02212015 2022-03-22

EVA

Phase 2 Terminated

26 enrolled 16 charts

Hemangiosarcoma

NCT01532687 2021-09-27

Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

Phase 2 Completed

54 enrolled 12 charts

Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

NCT01543802 2021-01-26

NOPASS

Phase 2 Terminated

Sarcoma

NCT03139331 2021-01-05

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

Phase 1 Completed

Sarcoma

NCT02300545 2020-08-05

Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

Phase 2 Completed

56 enrolled 11 charts

Sarcoma

NCT01446809 2020-04-13

Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

Phase NA Completed

23 enrolled 16 charts

Sarcoma

NCT01593748 2020-04-06

A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

Phase 2 Completed

90 enrolled 12 charts

Sarcoma

NCT01392352 2020-02-13

HYPAZ

Phase 2 Terminated

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Glioblastoma, Hypertension, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT01442662 2020-01-31

LMS03

Phase 2 Completed

Leiomyosarcoma, Neoplasm Metastasis

NCT02795819 2019-10-24

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Phase 1 Terminated

6 enrolled 12 charts

GenitourinarySarcoma

Carcinoma, Renal Cell, Neoplasm Metastasis, Sarcoma

NCT02575066 2019-06-27

PASART-2

Phase 2 Terminated

Sarcoma

NCT01438554 2018-08-29

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

Phase 1 Completed

GastrointestinalHead & NeckSarcoma

Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma

NCT03275558 2018-07-19

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Phase 1 Withdrawn

Glioblastoma, Glioma, Gliosarcoma

NCT01418001 2018-01-11

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Phase 1/2 Terminated

5 enrolled 6 charts

Leiomyosarcoma, Sarcoma, Neurofibrosarcoma, Histiocytoma, Histiocytoma, Malignant Fibrous

NCT01012362 2017-12-28

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Phase 1 Terminated

31 enrolled 12 charts

BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT01995981 2017-12-19

PREDICT

Sarcoma

NCT02113826 2017-11-06

Pazopanib for Metastatic Alveolar Soft Part Sarcoma

Phase 2 Terminated

Sarcoma, Alveolar Soft Part

NCT02342600 2017-10-12

SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

Phase 2 Withdrawn

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03149120 2017-08-22

Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

Phase 2 Withdrawn

Neoplasm Metastasis, Sarcoma

NCT01861951 2017-08-21

EPAZ

Phase 2 Completed

Sarcoma

NCT01524848 2017-05-10

PAGIST

Phase 2 Completed

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01391611 2017-04-07

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

Phase 2 Terminated

25 enrolled 7 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01506596 2017-02-15

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Phase 2 Completed

42 enrolled 9 charts

Liposarcoma

NCT01059656 2016-07-01

DFSP-PAZO

Phase 2 Terminated

Dermatofibrosarcoma

NCT01719302 2016-06-16

Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

Phase 1/2 Completed

Sarcoma

NCT01323400 2016-02-25

PAZOGIST

Phase 2 Completed

GIST

NCT01985295 2015-10-09

PASART-1

Phase 1 Completed

Sarcoma